Cytokinetics (CYTK)
NASDAQ: CYTK
· Real-Time Price · USD
32.46
-0.27 (-0.82%)
At close: Jun 20, 2025, 10:32 AM
-0.82% (1D)
| Bid | 32.43 |
| Market Cap | 3.88B |
| Revenue (ttm) | 19.22M |
| Net Income (ttm) | -615.26M |
| EPS (ttm) | -5.29 |
| PE Ratio (ttm) | -6.14 |
| Forward PE | -6.46 |
| Analyst | Buy |
| Ask | 32.46 |
| Volume | 262,512 |
| Avg. Volume (20D) | 2,111,793 |
| Open | 32.81 |
| Previous Close | 32.73 |
| Day's Range | 32.34 - 33.17 |
| 52-Week Range | 29.31 - 61.38 |
| Beta | 0.59 |
About CYTK
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CYTK
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CYTK stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Cytokinetics is scheduled to release its earnings on Aug 7, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-12.98%
Cytokinetics shares are trading lower after the co...
Unlock content with
Pro Subscription
1 month ago
+0.19%
Cytokinetics shares are trading lower after the company announced the FDA has extended the Prescription Drug User Fee Act action date for Aficamten.
